Drug firm SeQuent Scientific today said its animal healthcare arm Alivira has received approval for registration of three products in Ukraine.
The products have already been shipped to Ukraine and will be launched shortly,
SeQuent Scientific said in a filing
to BSE.
Alivira MD Manish Gupta said: "Our entry into Ukraine sets us up nicely to cement and expand our business interests in other CIS countries."
Alivira's differentiated product profile is well poised to drive the industry's transition from treatment to prevention products, he added.
Ukraine would make a significant contribution to Alivira's growth as another six products are under registration, SeQuent Scientific said.
Shares of SeQuent Scientific today closed 0.20 per cent higher at Rs 124.05 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
